Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Caris Life Sciences
Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence™
CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of data identifying multiple novel biomarkers as potential targets for immunotherapeutic agents in triple negative breast cancer (TNBC), an aggressive form of breast cancer in which the cancer cells lack estrogen receptors (ER), progesterone receptors (PR), and large amounts of the HER2/neu protein. This oral presentation, presented at the 50th annual meeting of ASCO, was performed as sponsored research at Mayo Clinic in Phoenix, Ariz., utilizing Caris Molecular Intelligence™, Caris' comprehensive tumor profiling service.
In the study, researchers analyzed 511 TNBC samples to examine the biomarkers involved in immune evasion as potential therapeutic targets, with particular focus on programmed death ligand 1 (PD-L1) and its association with other biological pathways. Their multiplatform approach included whole genome messenger RNA (mRNA) expression, protein expression via immunohistochemistry (IHC), gene copy number changes via in situ hybridization (ISH), and gene sequencing. Thirty six of the samples were validated using the IHC platform. This research revealed how expression of immune regulatory targets in the TNBC population suggests that immune-targeted therapies may be effective in certain patients. Their findings are considered especially timely, given the growing interest in immunotherapy as a potential treatment option in TNBC and other tumor types.
"Targeted treatment options for triple negative breast cancer have historically been quite limited," said lead investigator Barbara Pockaj, M.D., at the Mayo Clinic in Phoenix, Ariz. "While the results need further investigation, they illustrate how use of multiplatform molecular profiling technologies can identify novel biomarkers as potential immunotherapeutic targets in TNBC and other difficult-to-treat cancers."
Several highlights from this clinical study include previously unreported findings in TNBC:
"This dataset underscores the importance of our partnership with the prestigious Mayo Clinic, as it illustrates how a comprehensive approach to molecular profiling can enhance the accuracy and specificity of tumor characterization in individual patients with triple negative breast cancer, potentially facilitating therapeutic decision-making," noted Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. "Caris is now examining PD-1 and PD-L1 in a broad variety of tumor types to better identify patients subsets that are likely to respond to this new class of therapy, which is being featured so highly at ASCO this year. Ongoing research of the biomarkers identified in this study will help further elucidate their associations with response to specific agents, possibly leading to improved treatment outcomes for patients with TNBC and other types of cancer."
About Caris Molecular Intelligence™
Caris Molecular Intelligence™, the industry's leading cancer molecular profiling service, helps oncologists treat cancer smarter by delivering the most potential treatment options for patients. This service has been used by more than 6,000 oncologists to develop individualized and actionable treatment plans for more than 60,000 cancer patients in 59 countries across the globe. Caris Molecular Intelligence integrates the latest relevant panomics data - the combination of genes, proteins, molecular pathways, and unique patient characteristics - from clinical studies in cancer and cancer biology to identify the most clinically actionable drug associations approved by the U.S. Food & Drug Administration or in active clinical trials in the United States. Beyond standard DNA analysis, Caris Molecular Intelligence assesses all relevant biological components, such as RNA, protein expression and gene amplification levels, to provide oncologists with the most treatment options for their patients. Currently, Caris can identify therapeutic guidance for up to 51 drug associations, far exceeding the 19 that can be identified using next-generation sequencing alone. This therapeutic guidance is electronically delivered to the ordering physician in an easy-to-read report that enables development of tailored treatment plans. For more information on Caris Molecular Intelligence, visit www.carismolecularintelligence.com.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry's first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient's cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.
©2012 PR Newswire. All Rights Reserved.